Disappointing economic data from China sent the markets down to a lower open with the Dow falling 71 points to 17,752. Nasdaq lost 13 points to 4,730.
On the upside
Achillion Pharmaceuticals (Nasdaq: ACHN) reported upbeat updated interim results from a Phase 2 study to evaluate ACH-3102 in combination with sofosbuvir to treat naive genotype 1 HCV-infected patients.
Atossa Genetics (Nasdaq: ATOS) signed a national distribution agreement with Thermo Fisher Scientific for the FullCYTE Breast Aspirator.
Stifel Nicolaus upgraded Conn’s (Nasdaq: CONN) from a Hold rating to a Buy rating and set a $33 price target.
On the downside
Fifth Street Finance (Nasdaq: FSC) fell to a loss for the first quarter.
Renewed concerns that Greece may exit the euro weighed down shares of National Bank of Greece (NYSE: NBG).
Speed Commerce (Nasdaq: SPDC) widened third quarter losses and lowered its full year outlook.
In the broad market, declining issues outpaced advancers by a margin of more than 9 to 7 on the NYSE and by more than 5 to 3 on Nasdaq. The broader S&P 500 slipped 2 points to 2052. Bitcoin lost $5 to $217.
